

L Number	Hits	Search Text	DB	Time stamp
1	66643	peptidase or protease or proteinase	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/26 14:54
7	3178	(brain or neuronal) near2 ((app) or (amyloid precursor protein))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/26 14:55
13	11	(peptidase or protease or proteinase) near3 ((brain or neuronal) near2 ((app) or (amyloid precursor protein)))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/26 14:55

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653sxs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEX enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 20	EVENTLINE will be removed from STN
NEWS	28	Mar 24	PATDPAFULL now available on STN
NEWS	29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	30	Apr 11	Display formats in DGENE enhanced
NEWS	31	Apr 14	MEDLINE Reload
NEWS	32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS	34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	35	Apr 28	RDISCLOSURE now available on STN
NEWS	36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	38	May 15	Supporter information for ENCOMPAT and ENCOMPLIT updated
NEWS	39	May 16	CHEMREACT will be removed from STN
NEWS	40	May 19	Simultaneous left and right truncation added to WSCA
NEWS	41	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
 MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
 AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:00:42 ON 26 MAY 2003

=> File bioscience health medicine meetings pharmacology research toxicology

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'ADISCTI' ENTERED AT 14:00:52 ON 26 MAY 2003

COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 14:00:52 ON 26 MAY 2003

COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 14:00:52 ON 26 MAY 2003

COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 14:00:52 ON 26 MAY 2003

FILE 'ANABSTR' ENTERED AT 14:00:52 ON 26 MAY 2003

COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 14:00:52 ON 26 MAY 2003

COPYRIGHT 2003 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 14:00:52 ON 26 MAY 2003

COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 14:00:52 ON 26 MAY 2003

COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All
 rights reserved

FILE 'BIOSIS' ENTERED AT 14:00:52 ON 26 MAY 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ENTERED AT 14:00:52 ON 26 MAY 2003

COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHDS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHNO' ENTERED AT 14:00:52 ON 26 MAY 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 14:00:52 ON 26 MAY 2003

COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 14:00:52 ON 26 MAY 2003

FILE 'CAPLUS' ENTERED AT 14:00:52 ON 26 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (c) 2003 DECHEMA eV

FILE 'CEN' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 14:00:52 ON 26 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DDFB' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DDFU' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DGENE' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGB' ACCESS NOT AUTHORIZED

FILE 'DRUGLAUNCH' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ACCESS NOT AUTHORIZED

FILE 'DRUGUPDATES' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 14:00:52 ON 26 MAY 2003

FILE 'FOMAD' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'GENBANK' ENTERED AT 14:00:52 ON 26 MAY 2003

FILE 'HEALSAFE' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 14:00:52 ON 26 MAY 2003

FILE 'NIOSHTIC' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 14:00:52 ON 26 MAY 2003
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2003)

FILE 'NUTRACEUT' ENTERED AT 14:00:52 ON 26 MAY 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 14:00:52 ON 26 MAY 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 WIPO

FILE 'PHAR' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 14:00:52 ON 26 MAY 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Prous Science

FILE 'TOXCENTER' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 ACS

FILE 'USPATFULL' ENTERED AT 14:00:52 ON 26 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:00:52 ON 26 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'VETU' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CBNB' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (c) 2003 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CHEMLIST' ENTERED AT 14:00:52 ON 26 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CSNB' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ENERGY' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (c) 2003 USDOE for the IEA-Energy Technology Data Exchange (ETDE)

FILE 'HSDB' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 NATIONAL LIBRARY OF MEDICINE

FILE 'INIS' ACCESS NOT AUTHORIZED

FILE 'IPA' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 American Society of Hospital Pharmacists (ASHP)

FILE 'MSDS-CCOHS' ENTERED AT 14:00:52 ON 26 MAY 2003

Copyright Notice: Permission to copy is not required for this file

FILE 'MSDS-OHS' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 MDL INFORMATION SYSTEMS (MDL)

FILE 'NAPRALERT' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'POLLUAB' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'RTECS' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government (DOC)

FILE 'IMOBILITY' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Society of Automotive Engineers, Inc.

FILE 'COMPENDEX' ENTERED AT 14:00:52 ON 26 MAY 2003
Compendex Compilation and Indexing (C) 2003
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'COMPUAB' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CONF' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (c) 2003 FIZ Karlsruhe

FILE 'ELCOM' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IMSDRUGCONF' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd.

FILE 'PAPERCHEM2' ENTERED AT 14:00:52 ON 26 MAY 2003
Paperchem2 compilation and indexing (C) 2003
Elsevier Engineering Information Inc. All rights reserved.

FILE 'SOLIDSTATE' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'BABS' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (c) 2003 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'DIOGENES' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 FOI Services, Inc. (FOI)

FILE 'INVESTEXT' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Thomson Financial Services, Inc. (TFS)

FILE 'USAN' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 U.S. Pharmacopeial Convention, Inc. (USPC)

FILE 'DKF' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Dokumentation Kraftfahrwesen e.V., Germany

FILE 'FORIS' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'FORKAT' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Bundesministerium fuer Bildung,
Wissenschaft, Forschung und Technologie (bmb+f)

FILE 'RUSSCI' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Andrigal Ltd.

FILE 'SOLIS' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'UFORDAT' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Umweltbundesamt, D-14191 Berlin (UBA)

FILE 'AQUIRE' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 US Environmental Protection Agency (EPA)

FILE 'ULIDAT' ENTERED AT 14:00:52 ON 26 MAY 2003
COPYRIGHT (C) 2003 Umweltbundesamt, D-14191 Berlin (UBA)

```
=> s peptidase or protease or proteinase
    27 FILES SEARCHED...
    61 FILES SEARCHED...
L1      1143939 PEPTIDASE OR PROTEASE OR PROTEINASE
```

```
=> s (brain or neuronal) (2A) app
    29 FILES SEARCHED...
    59 FILES SEARCHED...
L2      2298 (BRAIN OR NEURONAL) (2A) APP
```

```
=> s l1 (3A) l2
    56 FILES SEARCHED...
L3      18 L1 (3A) L2
```

```
=> s (Brain or neuronal) (2a) (amyloid precursor protein)
    13 FILES SEARCHED...
    23 FILES SEARCHED...
    38 FILES SEARCHED...
    54 FILES SEARCHED...
    68 FILES SEARCHED...
L4      1200 (BRAIN OR NEURONAL) (2A) (AMYLOID PRECURSOR PROTEIN)
```

```
=> s l4 or l2
    56 FILES SEARCHED...
L5      3224 L4 OR L2
```

```
=> l1 (3a) l5
L1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
```

```
=> s l1 (3a) l5
    59 FILES SEARCHED...
L6      58 L1 (3A) L5
```

```
=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l6
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGLAUNCH, DRUGMONOG2, DRUGUPDATES, FEDRIP, FOREGE, GENBANK, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, RDISCLOSURE, SYNTHLINE, CHEMLIST,
```


HSDB, MSDS-CCOHS, MSDS-OHS, RTECS, CONF, IMSDRUGCONF, DIOGENES, INVESTEXT, USAN, FORIS, FORKAT, UFORDAT, ACQUIRE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
DUPLICATE PREFERENCE IS 'BIOSIS, BIOTECHABS, BIOTECHNO, CAPLUS, DGENE, EMBASE, ESBIODBASE, JICST-EPLUS, MEDLINE, SCISEARCH, TOXCENTER, USPATFULL, WPINDEX, CBNB, INVESTEXT'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L6

L7 48 DUPLICATE REMOVE L6 (10 DUPLICATES REMOVED)

=> d l7 1-48 bib

L7 ANSWER 1 OF 48 CAPLUS COPYRIGHT 2003 ACS

AN 2002:937303 CAPLUS

DN 138:20443

TI Endocrine disruptor screening using DNA chips of endocrine
disruptor-responsive genes

IN Kondo, Akihiro; Takeda, Takeshi; Mizutani, Shigetoshi; Tsujimoto,
Yoshimasa; Takashima, Ryokichi; Enoki, Yuki; Kato, Ikunoshin

PA Takara Bio Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 386 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002355079	A2	20021210	JP 2002-69354	20020313
PRAI	JP 2001-73183	A	20010314		
	JP 2001-74993	A	20010315		
	JP 2001-102519	A	20010330		

L7 ANSWER 2 OF 48 USPATFULL

AN 2002:191539 USPATFULL

TI Full-length human cDNAs encoding potentially secreted proteins

IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE

Bougueleret, Lydie, Petit Lancy, SWITZERLAND

Jobert, Severin, Paris, FRANCE

PI US 2002102604 A1 20020801

AI US 2000-731872 A1 20001207 (9)

PRAI US 1999-169629P 19991208 (60)

US 2000-187470P 20000306 (60)

DT Utility

FS APPLICATION

LREP John Lucas, Ph.D., J.D., Genset Corporation, 10665 Srrento Valley Road,
San Diego, CA, 92121-1609

CLMN Number of Claims: 29

ECL Exemplary Claim: 1

DRWN 5 Drawing Page(s)

LN.CNT 28061

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 48 USPATFULL

AN 2002:32581 USPATFULL

TI Methods to treat alzheimer's disease

IN Hom, Roy, San Francisco, CA, UNITED STATES

Mamo, Shumeye S., Oakland, CA, UNITED STATES

Tung, Jay, Belmont, CA, UNITED STATES

Gailunas, Andrea, San Francisco, CA, UNITED STATES

John, Varghese, San Francisco, CA, UNITED STATES

Fang, Lawrence Y., Foster City, CA, UNITED STATES

PI US 2002019403 A1 20020214

AI US 2001-816876 A1 20010323 (9)

PRAI US 2000-191528P 20000323 (60)

DT Utility
FS APPLICATION
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903
CLMN Number of Claims: 63
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8655
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 48 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE
1
AN 2001:204410 BIOSIS
DN PREV200100204410
TI Expression of human brain carboxypeptidase B, a possible cleaving enzyme
for beta-amyloid precursor protein, in peripheral fluids.
AU Matsumoto, Akira (1); Motozaki, Kenjiro; Seki, Tsuneyoshi; Sasaki, Ryohei;
Kawabe, Tetsuya
CS (1) Department of Radiation Biophysics and Genetics, Kobe University
School of Medicine, Kusunoki-cho chuo-ki 7-5-1, Kobe, 650-0017:
amat@med.kobe-u.ac.jp Japan
SO Neuroscience Research, (March, 2001) Vol. 39, No. 3, pp. 313-317. print.
ISSN: 0168-0102.
DT Article
LA English
SL English

L7 ANSWER 5 OF 48 WPINDEX (C) 2003 THOMSON DERWENT
AN 2000-687534 [67] WPINDEX
DNN N2000-508290 DNC C2000-209319
TI Human brain carboxypeptidase B isolated from the hippocampus useful for
screening agents for the treatment of Alzheimer's and other brain
disorders.
DC B04 D16 S03
IN MATSUMOTO, A
PA (MATS-I) MATSUMOTO A
CYC 92
PI WO 2000066717 A1 20001109 (200067)* JA 84p
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ
EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK
SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2000043166 A 20001117 (200111)
EP 1179588 A1 20020213 (200219) EN
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI
JP 2000615742 X 20021203 (200309)
ADT WO 2000066717 A1 WO 2000-JP2878 20000501; AU 2000043166 A AU 2000-43166
20000501; EP 1179588 A1 EP 2000-922936 20000501, WO 2000-JP2878 20000501;
JP 2000615742 X JP 2000-615742 20000501, WO 2000-JP2878 20000501
FDT AU 2000043166 A Based on WO 200066717; EP 1179588 A1 Based on WO
200066717; JP 2000615742 X Based on WO 200066717
PRAI JP 1999-125169 19990430

L7 ANSWER 6 OF 48 USPATFULL
AN 1999:155781 USPATFULL
TI Arylsulfonamides as phospholipase A.sub.2 inhibitors
IN John, Varghese, San Francisco, CA, United States
Rydel, Russell E., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5994398 19991130

AI US 1996-766554 19961211 (8)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Ford, John M.; Assistant Examiner: Kifle, Bruck
 LREP Townsend & Townsend & Crew
 CLMN Number of Claims: 40
 ECL Exemplary Claim: 1
 DRWN 5 Drawing Figure(s); 2 Drawing Page(s)
 LN.CNT 1939
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 48 CBNB COPYRIGHT 2003 EI
 AN 15(45):64780 CBNB
 TI Decade-long search yields elusive Alzheimer's enzyme.
 SO Biotechnology Newswatch (1 Nov 1999), 1,3, (200-899 words)
 ISSN: 0275-3685
 DT Journal
 LA English
 PY 1999

L7 ANSWER 8 OF 48 USPATFULL
 AN 1998:4424 USPATFULL
 TI Identification of phospholipase A2 inhibitors in A.beta.
 peptide-mediated neurodegenerative disease
 IN Rydel, Russell E., Belmont, CA, United States
 Dappen, Michael S., San Bruno, CA, United States
 PA Athena Neurosciences, Inc., San Francisco, CA, United States (U.S.
 corporation)
 PI US 5707821 19980113
 AI US 1995-476464 19950607 (8)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Lau, Kawai
 LREP Duvall, Esq., Jean, Storella, Esq., JohnTownsend and Townsend and Crew
 CLMN Number of Claims: 7
 ECL Exemplary Claim: 1
 DRWN 12 Drawing Figure(s); 9 Drawing Page(s)
 LN.CNT 1580
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 48 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:83026 CAPLUS
 DN 128:280072
 TI A human brain proteolytic activity capable of cleaving natural
 .beta.-amyloid precursor protein is affected by its substrate
 glycoconjugates
 AU Matsumoto, Akira; Matsumoto, Reiko; Enomoto, Taira; Itoh, Kyoko
 CS Chuo-ku, Kusunoki-cho 7-5-1, Department of Radiation Biophysics and
 Genetics, Kobe University School of Medicine, Kobe, Japan
 SO Neuroscience Letters (1998), 242(2), 109-113
 CODEN: NELED5; ISSN: 0304-3940
 PB Elsevier Science Ireland Ltd.
 DT Journal
 LA English

L7 ANSWER 10 OF 48 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:246789 CAPLUS
 DN 126:315931
 TI Amyloid precursor proteins protect neurons of transgenic mice against
 acute and chronic excitotoxic injuries in vivo
 AU Masliah, E.; Westland, C. E.; Rockenstein, E. M.; Abraham, C. R.; Mallory,
 M.; Veinberg, I.; Sheldon, E.; Mucke, L.
 CS Departments of Neurosciences and Pathology, University of California at
 San Diego, La Jolla, CA, 92093-0624, USA

SO Neuroscience (Oxford) (1997), 78(1), 135-146
CODEN: NRSCDN; ISSN: 0306-4522
PB Elsevier
DT Journal
LA English

L7 ANSWER 11 OF 48 CAPLUS COPYRIGHT 2003 ACS
AN 1996:304682 CAPLUS
DN 125:7373
TI A novel brain cysteine protease forms an SDS stable complex with the
.beta.-amyloid precursor protein
AU Chang, Tien; Abraham, Carmela R.
CS School of Medicine, Boston University, Boston, MA, 02118, USA
SO Annals of the New York Academy of Sciences (1996), 777 (Neurobiology of
Alzheimers Disease), 183-188
CODEN: ANYAA9; ISSN: 0077-8923
PB New York Academy of Sciences
DT Journal
LA English

L7 ANSWER 12 OF 48 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1996:452988 BIOSIS
DN PREV199699175344
TI Hydrolysis of amyloid precursor protein (**APP**) by a **brain**
acid protease.
AU Malik, M. N.; Wen, G. Y.; Wisniewski, H. M.
CS New York State Inst. Basic Res. Dev. Disabilities, 1050 Forest Hill Road,
Staten Island, NY 10314 USA
SO Neurobiology of Aging, (1996) Vol. 17, No. 4 SUPPL., pp. S104-S105.
Meeting Info.: Fifth International Conference on Alzheimer's Disease and
Related Disorders Osaka, Japan July 24-29, 1996
ISSN: 0197-4580.
DT Conference
LA English

L7 ANSWER 13 OF 48 USPATFULL
AN 95:50068 USPATFULL
TI Detection of brain .alpha.1-antichymotrypsin
IN Johnson-Wood, Kelly, Belmont, CA, United States
Schenk, Dale, Pacifica, CA, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5422244 19950606
AI US 1992-880216 19920505 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Bidwell, Carol E.
CLMN Number of Claims: 26
ECL Exemplary Claim: 17
DRWN 3 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 48 CAPLUS COPYRIGHT 2003 ACS
AN 1994:292870 CAPLUS
DN 120:292870
TI Generation of potentially amyloidogenic fragments from the beta-
amyloid precursor protein by **brain**
serine proteases
AU Martin, Brownwyn L.
CS Boston Univ., Boston, MA, USA
SO (1994) 342 pp. Avail.: Univ. Microfilms Int., Order No. DA9330150
From: Diss. Abstr. Int. B 1993, 54(6), 3048
DT Dissertation

LA English

L7 ANSWER 15 OF 48 CAPLUS COPYRIGHT 2003 ACS
 AN 1994:652968 CAPLUS
 DN 121:252968
 TI Increased neuronal .beta.-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1.alpha. immunoreactivity
 AU Sheng, Jin G.; Boop, Frederick A.; Mrak, Robert E.; Griffin, W. Sue T.
 CS Arkansas Children's Hospital Research Center, Departments of Anatomy, Neurosurgery, Pathology and Pediatrics, Little Rock, AR, USA
 SO Journal of Neurochemistry (1994), 63(5), 1872-9
 CODEN: JONRA9; ISSN: 0022-3042
 DT Journal
 LA English

L7 ANSWER 16 OF 48 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:47779 CAPLUS
 DN 122:181691
 TI Potential .beta.PP-processing proteinase activities from Alzheimer's and control brain tissues
 AU Lador, Uri S.; Wang, Gary T.; Klein, William L.; Holzman, Thomas F.; Krafft, Grant A.
 CS Drug Design Delivery, Abbott Laboratories, Abbott Park, IL, 60064, USA
 SO Journal of Protein Chemistry (1994), 13(4), 357-66
 CODEN: JPCHD2; ISSN: 0277-8033
 DT Journal
 LA English

L7 ANSWER 17 OF 48 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:390035 CAPLUS
 DN 123:50670
 TI Cleavage of fluorogenic substrates for APP-processing proteases by human brain extracts. Ca²⁺-substrate interaction is responsible for Ca²⁺ stimulation of the neural protease activity
 AU Wang, Gary T.; Lador, Uri S.; Holzman, Thomas F.; Klein, William L.; Krafft, Grant A.
 CS Pharmaceutical Product Division, Abbott Laboratories, Abbott Park, IL, 60064, USA
 SO Molecular and Chemical Neuropathology (1994), 23(2/3), 191-9
 CODEN: MCHNEM; ISSN: 1044-7393
 DT Journal
 LA English

L7 ANSWER 18 OF 48 CAPLUS COPYRIGHT 2003 ACS
 AN 1994:241734 CAPLUS
 DN 120:241734
 TI .beta.-amyloid precursor protein fragments and lysosomal dense bodies are found in rat brain neurons after ventricular infusion of leupeptin
 AU Hajimohammadreza, I.; Anderson, V. E. R.; Cavanagh, J. B.; Seville, M. P.; Nolan, C. C.; Anderton, B. H.; Leigh, P. N.
 CS University Department of Neurology, London, SE5 8AF, UK
 SO Brain Research (1994), 640(1-2), 25-32
 CODEN: BRREAP; ISSN: 0006-8993
 DT Journal
 LA English

L7 ANSWER 19 OF 48 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 2
 AN 1993:601106 CAPLUS
 DN 119:201106
 TI Identification of a chymotrypsin-like mast cell protease in rat brain capable of generating the N-terminus of the Alzheimer amyloid .beta.-protein
 AU Nelson, Robert B.; Siman, Robert; Iqbal, Mohamed A.; Potter, Huntington

CS Dep. Neurobiol., Harvard Med. Sch., Boston, MA, 02115, USA
SO Journal of Neurochemistry (1993), 61(2), 567-77
CODEN: JONRA9; ISSN: 0022-3042
DT Journal
LA English

L7 ANSWER 20 OF 48 CAPLUS COPYRIGHT 2003 ACS
AN 1994:479550 CAPLUS
DN 121:79550
TI Studies on brain proteases capable of degrading the .beta. amyloid precursor protein
AU Abraham, Carmela R.; Papastoitsis, Gregory; Razzaboni, Bronwyn L.; Kanemaru, Kazutomi; Pietropaolo, Michael; Conn, Kelly-Jo; Meckelein, Barbara
CS Sch. Med., Boston Univ., Boston, MA, 02118, USA
SO Portland Press Proceedings (1993), 6(PROTEOLYSIS AND PROTEIN TURNOVER), 197-202
CODEN: POPPEF; ISSN: 0966-4068
DT Journal; General Review
LA English

L7 ANSWER 21 OF 48 CAPLUS COPYRIGHT 2003 ACS
AN 1992:509327 CAPLUS
DN 117:109327
TI .beta.-Amyloid precursor protein cleavage by a membrane-bound protease
AU Sisodia, Sangram S.
CS Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205, USA
SO Proceedings of the National Academy of Sciences of the United States of America (1992), 89(13), 6075-9
CODEN: PNASA6; ISSN: 0027-8424
DT Journal
LA English

L7 ANSWER 22 OF 48 CAPLUS COPYRIGHT 2003 ACS
AN 1993:405295 CAPLUS
DN 119:5295
TI Association and release of the amyloid protein precursor of Alzheimer's disease from chick brain extracellular matrix
AU Small, D. H.; Nurcombe, V.; Moir, R.; Michaelson, S.; Monard, D.; Beyreuther, K.; Masters, C. L.
CS Dep. Pathol., Univ. Melbourne, Parkville, 3052, Australia
SO Journal of Neuroscience (1992), 12(11), 4143-50
CODEN: JNRSDS; ISSN: 0270-6474
DT Journal
LA English

L7 ANSWER 23 OF 48 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1992:296904 BIOSIS
DN BR43:9254
TI CO-DISTRIBUTION OF PROTEASE NEXIN-1 AND **PROTEASE** NEXIN-2-**APP-SEC** IN **BRAINS** OF NON-HUMAN PRIMATES.
AU WAGNER S L; VAN NOSTRAND W E; LAU A L; SUZUKI M; FARROW J S; BARTUS R; SCHUPPEK R; NGUYEN A; COTMAN C W; CUNNINGHAM D D
CS SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES INC., LA JOLLA, CALIF. 92037.
SO KEYSTONE SYMPOSIUM ON ADVANCES IN UNDERSTANDING NEURODEGENERATIVE DISORDERS, BIG SKY, MONTANA, USA, MARCH 28-APRIL 4, 1992. J CELL BIOCHEM SUPPL. (1992) 0 (16 PART E), 213.
CODEN: JCBSD7.
DT Conference
FS BR; OLD
LA English

L7 ANSWER 24 OF 48 CAPLUS COPYRIGHT 2003 ACS

AN 1992:631521 CAPLUS
 DN 117:231521
 TI A calcium-stimulated serine protease from monkey brain degrades the .beta.-amyloid precursor protein
 AU Razzaboni, Bronwyn L.; Papastoitsis, Gregory; Koo, Edward H.; Abraham, Carmela R.
 CS Sch. Med., Boston Univ., Boston, MA, 02118, USA
 SO Brain Research (1992), 589(2), 207-16
 CODEN: BRREAP; ISSN: 0006-8993
 DT Journal
 LA English

L7 ANSWER 25 OF 48 CAPLUS COPYRIGHT 2003 ACS
 AN 1992:548472 CAPLUS
 DN 117:148472
 TI Two-way cleavage of .beta.-amyloid protein precursor by multicatalytic proteinase
 AU Kojima, Shinichi; Omori, Motoko
 CS Res. Inst., Sumitomo Pharm. Co., Osaka, 554, Japan
 SO FEBS Letters (1992), 304(1), 57-60
 CODEN: FEBLAL; ISSN: 0014-5793
 DT Journal
 LA English

L7 ANSWER 26 OF 48 CAPLUS COPYRIGHT 2003 ACS
 AN 1992:548494 CAPLUS
 DN 117:148494
 TI .alpha.2-Macroglobulin and other proteinase inhibitors do not interfere with the secretion of amyloid precursor protein in mouse neuroblastoma cells
 AU De Strooper, Bart; Van Leuven, Fred; Van den Berghe, Herman
 CS Cent. Hum. Genet., Univ. Leuven, Louvain, Belg.
 SO FEBS Letters (1992), 308(1), 50-3
 CODEN: FEBLAL; ISSN: 0014-5793
 DT Journal
 LA English

L7 ANSWER 27 OF 48 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 AN 1992:245767 BIOSIS
 DN BR42:116067
 TI A SERINE PROTEASE FROM MONKEY AND ALZHEIMER'S BRAIN AND A CYSTEINE PROTEASE FROM ALZHEIMER'S BRAIN DEGRADE THE AMYLOID PRECURSOR PROTEIN.
 AU ABRAHAM C R; RAZZABONI B; PAPASTOITSIS G
 CS ARTHRITIS CENT., BOSTON UNIV. SCH. MED., BOSTON, MASS. 02118.
 SO 21ST ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, NEW ORLEANS, LOUISIANA, USA, NOVEMBER 10-15, 1991. SOC NEUROSCI ABSTR. (1991) 17 (1-2), 1105.
 CODEN: ASNEE5.
 DT Conference
 FS BR; OLD
 LA English

L7 ANSWER 28 OF 48 CAPLUS COPYRIGHT 2003 ACS
 AN 1991:119669 CAPLUS
 DN 114:119669
 TI A calcium-activated protease from Alzheimer's disease brain cleaves at the N-terminus of the amyloid .beta.-protein
 AU Abraham, Carmela R.; Driscoll, James; Potter, Huntington; Van Nostrand, William E.; Tempst, Paul
 CS Sch. Med., Boston Univ., Boston, MA, 02118, USA
 SO Biochemical and Biophysical Research Communications (1991), 174(2), 790-6
 CODEN: BBRCA9; ISSN: 0006-291X
 DT Journal

LA English

L7 ANSWER 29 OF 48 CAPLUS COPYRIGHT 2003 ACS
 AN 1991:79412 CAPLUS
 DN 114:79412
 TI Proteolytic cleavage of the Alzheimer's disease amyloid A4 precursor protein
 AU Ishiura, Shoichi
 CS Natl. Inst. Neurosci., NCNP, Tokyo, 187, Japan
 SO Journal of Neurochemistry (1991), 56(2), 363-9
 CODEN: JONRA9; ISSN: 0022-3042
 DT Journal; General Review
 LA English

L7 ANSWER 30 OF 48 CAPLUS COPYRIGHT 2003 ACS
 AN 1993:122247 CAPLUS
 DN 118:122247
 TI An immunohistochemical study of amyloid precursor proteins containing the proteinase inhibitor region (APPI) in the human neocortex
 AU Nakamura, Shinichi; Akiguchi, Ichiro; Kimura, Jun; Nakamura, Shigenobu; Tokushima, Yasuo; Kitaguchi, Nobuya; Takahashi, Yasuyuki; Shiojiri, Satoshi
 CS Fac. Med., Kyoto Univ., Kyoto, Japan
 SO International Congress Series (1991), 999(.beta.-Amyloid Precursor Proteins Neurotransm. Funct.), 26-37
 CODEN: EXMDA4; ISSN: 0531-5131
 DT Journal
 LA English

L7 ANSWER 31 OF 48 BIOTECHABS COPYRIGHT 2003 THOMSON DERWENT AND ISI
 AN 1990-12043 BIOTECHABS
 TI Monoclonal antibody preparation;
 against human brain amyloid precursor protein; mouse hybridoma
 construction; potential application in Alzheimer disease diagnosis
 PA Asahi-Chem.
 PI JP 02138995 28 May 1990
 AI JP 1988-290626 17 Nov 1988
 PRAI JP 1988-201998 15 Aug 1988; JP 1987-291404 18 Nov 1987
 DT Patent
 LA Japanese
 OS WPI: 1990-206694 [27]

L7 ANSWER 32 OF 48 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE
 4
 AN 1991:55121 BIOSIS
 DN BA91:33402
 TI ALZHEIMER AMYLOID BETA-PROTEIN PRECURSOR IN SPERM DEVELOPMENT.
 AU SHOJI M; KAWARABAYASHI T; HARIGAYA Y; YAMAGUCHI H; HIRAI S; KAMIMURA T; SUGIYAMA T
 CS DEP. NEUROL., GUNMA UNIV. SCH. MED., MAEBASHI, GUNMA 371, JPN.
 SO AM J PATHOL, (1990) 137 (5), 1027-1032.
 CODEN: AJPA44. ISSN: 0002-9440.
 FS BA; OLD
 LA English

L7 ANSWER 33 OF 48 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:609064 CAPLUS
 DN 113:209064
 TI Activity and expression of amyloid precursor proteins possessing proteinase inhibitor regions
 AU Kitaguchi, Nobuya; Shiojiri, Satoshi; Takahashi, Yasuyuki; Tokushima, Yasuo
 CS Bio-Sci. Lab., Asahi Chem. Ind. Co. Ltd., Fuji, 416, Japan
 SO Shinkei Kenkyu no Shinpo (1990), 34(3), 409-21

CODEN: SKNSAF; ISSN: 0001-8724

DT Journal; General Review
LA Japanese

L7 ANSWER 34 OF 48 CAPLUS COPYRIGHT 2003 ACS

AN 1991:604994 CAPLUS

DN 115:204994

TI Protease inhibitor and cholinergic system in Alzheimer's disease

AU Nakamura, Shigenobu; Tanaka, Seigo; Araki, Wataru; Tsuji, Teruyuki;
Kawashima, Shingo; Shiojiri, Satoshi; Takahashi, Yasuyuki; Kitaguchi,
Nobuya; Ito, Hirataka

CS Fac. Med., Kyoto Univ., Kyoto, Japan

SO Advances in Behavioral Biology (1990), 38A(Basic, Clin., Ther. Aspects
Alzheimer's Parkinson's Dis., Vol. 1), 41-6

CODEN: ADBBBW; ISSN: 0099-6246

DT Journal
LA English

L7 ANSWER 35 OF 48 BIOTECHABS COPYRIGHT 2003 THOMSON DERWENT AND ISI

AN 1989-05725 BIOTECHABS

TI Human senile plaque amyloid precursor protein and DNA;
protease-inhibitor gene cloning from cell culture and expression in
Escherichia coli; DNA sequence; DNA probe construction

PA Asahi-Chem.

PI EP 304013 22 Feb 1989

AI EP 1988-113283 16 Aug 1988

PRAI JP 1988-125660 25 May 1988; JP 1987-203298 15 Aug 1987

DT Patent

LA English

OS WPI: 1989-055458 [08]

L7 ANSWER 36 OF 48 CAPLUS COPYRIGHT 2003 ACS

AN 1990:53245 CAPLUS

DN 112:53245

TI Tissue-specific expression of three types of .beta.-protein precursor
mRNA: enhancement of protease inhibitor-harboring types in Alzheimer's
disease brain

AU Tanaka, Seigo; Shiojiri, Satoshi; Takahashi, Yasuyuki; Kitaguchi, Nobuya;
Ito, Hirataka; Kameyama, Masakuni; Kimura, Jun; Nakamura, Shigenobu; Ueda,
Kunihiro

CS Fac. Med., Kyoto Univ., Kyoto, 606, Japan

SO Biochemical and Biophysical Research Communications (1989), 165(3),
1406-14

CODEN: BBRCA9; ISSN: 0006-291X

DT Journal
LA English

L7 ANSWER 37 OF 48 JICST-EPlus COPYRIGHT 2003 JST

AN 890550938 JICST-EPlus

TI Molecular genetics of neurological disorders. Molecular biological
research on Alzheimer's disease.

AU KITAGUCHI NOBUYA; TAKAHASHI YASUYUKI

CS Asahikaseikogyo Seikagakuken

SO Shinkei Kenkyu no Shinpo (Advances in Neurological Sciences), (1989) vol.
33, no. 4, pp. 571-582. Journal Code: Z0693A (Fig. 8, Tbl. 1, Ref. 52)
ISSN: 0001-8724

CY Japan

DT Journal; General Review

LA Japanese

STA New

L7 ANSWER 38 OF 48 CAPLUS COPYRIGHT 2003 ACS

AN 1989:207058 CAPLUS

DN 110:207058

TI Identification of different .beta. amyloid cDNAs cloned from the brain of
a patient with sporadic Alzheimer's disease
AU Octave, J. N.; De Sauvage, F.; Macq, A. F.; Maloteaux, J. M.; Laterre, E.
C.
CS Lab. Neurochim., Univ. Cathol. Louvain, Brussels, B-1200, Belg.
SO Neurochemistry International (1989), 14(2), 163-6
CODEN: NEUIDS; ISSN: 0197-0186
DT Journal
LA English

L7 ANSWER 39 OF 48 DGENE (C) 2003 THOMSON DERWENT
AN AAB11461 Protein DGENE
TI Human brain carboxypeptidase B isolated from the hippocampus useful for
screening agents for the treatment of Alzheimer's and other brain
disorders -
IN Matsumoto A
PA (MATS-I) MATSUMOTO A.
PI WO 2000066717 A1 20001109 84p
AI WO 2000-JP2878 20000501
PRAI JP 1999-125169 19990430
DT Patent
LA Japanese
OS 2000-687534 [67]
DESC Human brain carboxypeptidase B protein SEQ ID NO 9.

L7 ANSWER 40 OF 48 DGENE (C) 2003 THOMSON DERWENT
AN AAB11460 Protein DGENE
TI Human brain carboxypeptidase B isolated from the hippocampus useful for
screening agents for the treatment of Alzheimer's and other brain
disorders -
IN Matsumoto A
PA (MATS-I) MATSUMOTO A.
PI WO 2000066717 A1 20001109 84p
AI WO 2000-JP2878 20000501
PRAI JP 1999-125169 19990430
DT Patent
LA Japanese
OS 2000-687534 [67]
DESC Human brain carboxypeptidase B protein SEQ ID NO 5.

L7 ANSWER 41 OF 48 DGENE (C) 2003 THOMSON DERWENT
AN AAB11459 Protein DGENE
TI Human brain carboxypeptidase B isolated from the hippocampus useful for
screening agents for the treatment of Alzheimer's and other brain
disorders -
IN Matsumoto A
PA (MATS-I) MATSUMOTO A.
PI WO 2000066717 A1 20001109 84p
AI WO 2000-JP2878 20000501
PRAI JP 1999-125169 19990430
DT Patent
LA Japanese
OS 2000-687534 [67]
DESC Human brain carboxypeptidase B protein SEQ ID NO 4.

L7 ANSWER 42 OF 48 DGENE (C) 2003 THOMSON DERWENT
AN AAB11458 Protein DGENE
TI Human brain carboxypeptidase B isolated from the hippocampus useful for
screening agents for the treatment of Alzheimer's and other brain
disorders -
IN Matsumoto A
PA (MATS-I) MATSUMOTO A.
PI WO 2000066717 A1 20001109 84p
AI WO 2000-JP2878 20000501

PRAI JP 1999-125169 19990430
 DT Patent
 LA Japanese
 OS 2000-687534 [67]
 DESC Human brain carboxypeptidase B protein SEQ ID NO 3.

L7 ANSWER 43 OF 48 DGENE (C) 2003 THOMSON DERWENT
 AN AAB11457 Protein DGENE
 TI Human brain carboxypeptidase B isolated from the hippocampus useful for screening agents for the treatment of Alzheimer's and other brain disorders -
 IN Matsumoto A
 PA (MATS-I) MATSUMOTO A.
 PI WO 2000066717 A1 20001109 84p
 AI WO 2000-JP2878 20000501
 PRAI JP 1999-125169 19990430
 DT Patent
 LA Japanese
 OS 2000-687534 [67]
 CR N-PSDB: AAC81962
 DESC Human brain carboxypeptidase B protein.

L7 ANSWER 44 OF 48 DGENE (C) 2003 THOMSON DERWENT
 AN AAC81965 DNA DGENE
 TI Human brain carboxypeptidase B isolated from the hippocampus useful for screening agents for the treatment of Alzheimer's and other brain disorders -
 IN Matsumoto A
 PA (MATS-I) MATSUMOTO A.
 PI WO 2000066717 A1 20001109 84p
 AI WO 2000-JP2878 20000501
 PRAI JP 1999-125169 19990430
 DT Patent
 LA Japanese
 OS 2000-687534 [67]
 DESC Human brain carboxypeptidase B DNA primer SEQ ID NO 8.

L7 ANSWER 45 OF 48 DGENE (C) 2003 THOMSON DERWENT
 AN AAC81964 DNA DGENE
 TI Human brain carboxypeptidase B isolated from the hippocampus useful for screening agents for the treatment of Alzheimer's and other brain disorders -
 IN Matsumoto A
 PA (MATS-I) MATSUMOTO A.
 PI WO 2000066717 A1 20001109 84p
 AI WO 2000-JP2878 20000501
 PRAI JP 1999-125169 19990430
 DT Patent
 LA Japanese
 OS 2000-687534 [67]
 DESC Human brain carboxypeptidase B DNA primer SEQ ID NO 7.

L7 ANSWER 46 OF 48 DGENE (C) 2003 THOMSON DERWENT
 AN AAC81963 DNA DGENE
 TI Human brain carboxypeptidase B isolated from the hippocampus useful for screening agents for the treatment of Alzheimer's and other brain disorders -
 IN Matsumoto A
 PA (MATS-I) MATSUMOTO A.
 PI WO 2000066717 A1 20001109 84p
 AI WO 2000-JP2878 20000501
 PRAI JP 1999-125169 19990430
 DT Patent
 LA Japanese

OS 2000-687534 [67]
DESC Human brain carboxypeptidase B DNA primer SEQ ID NO 6.

L7 ANSWER 47 OF 48 DGENE (C) 2003 THOMSON DERWENT
AN AAC81962 cDNA DGENE
TI Human brain carboxypeptidase B isolated from the hippocampus useful for
screening agents for the treatment of Alzheimer's and other brain
disorders -
IN Matsumoto A
PA (MATS-I) MATSUMOTO A.
PI WO 2000066717 A1 20001109 84p
AI WO 2000-JP2878 20000501
PRAI JP 1999-125169 19990430
DT Patent
LA Japanese
OS 2000-687534 [67]
CR P-PSDB: AAB11457
DESC Human brain carboxypeptidase B cDNA.

L7 ANSWER 48 OF 48 INVESTEXT COPYRIGHT 2003 TFS

AN 91:419901 INVESTEXT(tm) REPORT NUMBER:1145046
PGNO PAGE 7 OF 14
DN 1145046
TI Cephalon, Inc. - Company Report
AU Siegel, J.G.
CS HAMBRECHT & QUIST INCORPORATED; NEW YORK
CSR MID-ATLANTIC/MIDDLE ATLANTIC STATES; UNITED STATES OF AMERICA; NORTH
AMERICA
CSTY Financial center investment bank-broker
PD 9 Oct 1991
DT COMPANY REPORT
FS Text Page; COMPANY REPORT
WC 436

=>

<-----User Break----->

=> d 17 7 9 11 12 14 16 17 19 20 21 25 27 2829 33 bib ab

48 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE

The answer numbers requested are not in the answer set.

ENTER ANSWER NUMBER OR RANGE (1):d 17 7 9 11 12 14 16 17 19 20 21 25 27 28 29 33
bib ab

ANSWER NUMBERS NOT CORRECTLY SPECIFIED

Enter an answer number, Example: 10
several answer numbers, Example: 3,7,10
a range of answer numbers, Example: 5-10
or a combination of these. Example: 3,7,9-10,15

ENTER ANSWER NUMBER OR RANGE (1):7 9 11 12 14 16 17 19 20 21 25 27 28 29 33

L7 ANSWER 7 OF 48 CBNB COPYRIGHT 2003 EI

AN 15(45):84780 CBNB

TI Decade-long search yields elusive Alzheimer's enzyme.

SO Biotechnology Newswatch (1 Nov 1999), 1,3, (200-899 words)
ISSN: 0275-3685

DT Journal

LA English

PY 1999

AB Amgen researchers have discovered the gene responsible for producing betasecretase. This protease enzyme starts the development of Alzheimer's disease by cutting the **amyloid precursor protein** of healthy **brain** cells. A 2nd **protease** enzyme, gamma-secretase then cuts it again, causing a build up of beta-amyloid plaque in the brain. The Amgen team has not only identified the gene but also used it to produce beta-secretase and replicate the enzyme's amyloid precursor protein cutting action. It seems that a protease inhibitor (like those used against Aids) could be effective in treating Alzheimer's disease. Furthermore a single protease inhibitor might suffice. However it will be a long time before any new treatment reaches the market. There are still doubts about the development of Alzheimer's disease and the role gamma- secretase plays in it. The results of SmithKline Beecham's research into this enzyme should be presented at the annual Society for Neuroscience meeting. US biotechnology company Elan Pharmaceuticals has already patented a chemical which it says is beta-secretase, although this is not the same as Amgen's. Amgen itself has refused to comment on whether it is seeking to patent its discovery.

L7 ANSWER 9 OF 48 CAPLUS COPYRIGHT 2003 ACS

AN 1998:83026 CAPLUS

DN 128:280072

TI A human brain proteolytic activity capable of cleaving natural .beta.-amyloid precursor protein is affected by its substrate glycoconjugates

AU Matsumoto, Akira; Matsumoto, Reiko; Enomoto, Taira; Itoh, Kyoko

CS Chuo-ku, Kusunoki-cho 7-5-1, Department of Radiation Biophysics and Genetics, Kobe University School of Medicine, Kobe, Japan

SO Neuroscience Letters (1998), 242(2), 109-113
CODEN: NELED5; ISSN: 0304-3940

PB Elsevier Science Ireland Ltd.

DT Journal

LA English

AB Human brain proteins were partially purified by using arginine-Sepharose 4B affinity chromatog., which traps proteins having an affinity to certain groups of arginine residue, such as serine proteases and zymogens. Bound proteins were analyzed for binding and cleavage related to the brain .beta.-amyloid precursor protein (APP). They were then further sepd. and isolated using a preparative gel system having a liq.-phase collection

app., using a non-denaturing gel system. Each fractionated protein was also analyzed for the above activity using natural APP. Among these, we found several fractions that bind preferentially to APP treated with chondroitinase ABC but not to intact APP, and that also generate particular .beta.-amyloid contg. C-terminal peptides of APP via proteolysis. Our results suggest that sulfated glycoconjugates attached to APP play a role in the substrate specificity of APP for proteases, and also that the nature of natural APP processing mechanisms in vivo is very complex.

L7 ANSWER 11 OF 48 CAPLUS COPYRIGHT 2003 ACS

AN 1996:304682 CAPLUS

DN 125:7373

TI A novel brain cysteine protease forms an SDS stable complex with the .beta.-amyloid precursor protein

AU Chang, Tien; Abraham, Carmela R.

CS School of Medicine, Boston University, Boston, MA, 02118, USA

SO Annals of the New York Academy of Sciences (1996), 777(Neurobiology of Alzheimers Disease), 183-188

CODEN: ANYAA9; ISSN: 0077-8923

PB New York Academy of Sciences

DT Journal

LA English

AB Alzheimer's disease (AD) brain accumulates .beta.-protein (A.beta.) a peptide proteolytically derived from the .beta.-amyloid precursor protein (APP). The abnormal prodn. and aggregation of A.beta. have been implicated in the pathogenesis of the disease. The mechanism of prodn. of A.beta. in vivo is not yet clear; but endoproteases capable of degrading APP are likely to be involved in the process. The authors have isolated a protease from AD brain by following its activity in digesting a synthetic peptide of 10 amino acids derived from the APP sequence flanking the N-terminus of A.beta.. The protease was purified by a fractionation scheme including ammonium sulfate pptn. and column chromatog. using hydrophobic interaction, anion exchange, affinity, hydroxyapatite and size exclusion gels. The purity of the final product was assessed on a silver stained SDS gel by the presence of a single band. Microsequencing was performed following trypsin digestion of the sample. Internal peptide sequences were found to have sequence homol. to cysteine proteases in the database. The enzyme requires DTT for activity and can be inhibited by specific inhibitors of cysteine but not serine proteases. The purified enzyme has a pI of 5.0 and a native tetrameric structure with subunits of 48 kDa each. The enzyme is capable of digesting APP and generating a short peptide recognizable by antibodies specific to the C-terminus of APP. Interestingly, the purified protease also forms heat- and SDS-stable complexes with APP.

L7 ANSWER 12 OF 48 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 1996:452988 BIOSIS

DN PREV199699175344

TI Hydrolysis of amyloid precursor protein (APP) by a brain acid protease.

AU Malik, M. N.; Wen, G. Y.; Wisniewski, H. M.

CS New York State Inst. Basic Res. Dev. Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314 USA

SO Neurobiology of Aging, (1996) Vol. 17, No. 4 SUPPL., pp. S104-S105.

Meeting Info.: Fifth International Conference on Alzheimer's Disease and Related Disorders Osaka, Japan July 24-29, 1996

ISSN: 0197-4580.

DT Conference

LA English

L7 ANSWER 14 OF 48 CAPLUS COPYRIGHT 2003 ACS

AN 1994:292870 CAPLUS

DN 120:292870

TI Generation of potentially amyloidogenic fragments from the beta-
amyloid precursor protein by brain
serine proteases

AU Martin, Brownwyn L.

CS Boston Univ., Boston, MA, USA

SO (1994) 342 pp. Avail.: Univ. Microfilms Int., Order No. DA9330150
From: Diss. Abstr. Int. B 1993, 54(6), 3048

DT Dissertation

LA English

AB Unavailable

L7 ANSWER 16 OF 48 CAPLUS COPYRIGHT 2003 ACS

AN 1995:47779 CAPLUS

DN 122:181691

TI Potential .beta.PP-processing proteinase activities from Alzheimer's and
control brain tissues

AU Lador, Uri S.; Wang, Gary T.; Klein, William L.; Holzman, Thomas F.;
Krafft, Grant A.

CS Drug Design Delivery, Abbott Laboratories, Abbott Park, IL, 60064, USA

SO Journal of Protein Chemistry (1994), 13(4), 357-66

CODEN: JPCD2; ISSN: 0277-8033

DT Journal

LA English

AB Fluorogenic peptide substrates designed to encompass the reported
.alpha.-secretory and amyloidogenic cleavage sites of the amyloid-.beta.
precursor protein (.beta.PP) were used to analyze proteinase activities in
brain exts. from control patients and those with Alzheimer's disease (AD).
Activity against the secretory substrate at pH 7.5 in control and AD
brains produced a major endopeptidase cleavage at the Lys687-Leu688 bond
(.beta.PP770 numbering), consistent with the .beta.PP secretase cleavage.
Activity in control brains against the amyloidogenic substrate at pH 7.5
produced one cleavage at the Ala673-Glu674 bond, two residues C-terminal
to the amyloidogenic Met-Asp site. However, in three of four AD brains,
the major cleavage was at the Asp-Ala bond, one residue from the
amyloidogenic site. Both endopeptidase and carboxypeptidase activities in
AD brains were lower than in control brains. Proteinase activities
against the secretory substrate had a major optimum at pH 3.0-4.0 and
another at pH 6.0-7.5. Proteinase activities against the amyloidogenic
substrate had a major optimum at or below pH 3.0 and another at pH 6.0.
Using both substrates, activities at low pH were higher in AD brains than
in controls, while at pH above 6.5, activities in control brains were
higher than in AD. These results indicate that the levels of proteolytic
enzymes in AD brains are altered relative to controls.

L7 ANSWER 17 OF 48 CAPLUS COPYRIGHT 2003 ACS

AN 1995:390035 CAPLUS

DN 123:50670

TI Cleavage of fluorogenic substrates for APP-processing proteases by human
brain extracts. Ca²⁺-substrate interaction is responsible for Ca²⁺
stimulation of the neural protease activity

AU Wang, Gary T.; Lador, Uri S.; Holzman, Thomas F.; Klein, William L.;
Krafft, Grant A.

CS Pharmaceutical Product Division, Abbott Laboratories, Abbott Park, IL,
60064, USA

SO Molecular and Chemical Neuropathology (1994), 23(2/3), 191-9

CODEN: MCHNEM; ISSN: 1044-7393

DT Journal

LA English

AB The proteases that cleave amyloid precursor protein (APP) leading to
generation of amyloid A.beta. peptide are potential targets for
therapeutical intervention of Alzheimer disease. The authors have been
pursuing the identification and characterization of these proteases using
as probes the fluorogenic substrates encompassing the cleavage sites of
APP that were described recently (Wang, G. T.; Krafft, G. A., 1992). This

Zn#?

article describes results of expts. designed to examine the effect of Ca²⁺ on the cleavage of these substrates by human brain exts. Fluorogenic substrates encompassing either the N-terminal amyloidogenic cleavage site or the secretory cleavage site were synthesized in 5 formats with various peripheral residues. Incubation with exts. from normal brain tissue revealed that more neg. charged amyloidogenic substrates were less reactive and exhibited larger rate enhancement in the presence of Ca²⁺. The results imply that Ca²⁺ stimulation of substrate cleavage by brain proteases occurs primarily as a result of Ca²⁺-substrate interactions and caution against interpretations that invoke the involvement of Ca²⁺-stimulated proteases in A.beta. formation.

L7 ANSWER 19 OF 48 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 2
AN 1993:601106 CAPLUS
DN 119:201106
TI Identification of a chymotrypsin-like mast cell protease in rat brain capable of generating the N-terminus of the Alzheimer amyloid .beta.-protein
AU Nelson, Robert B.; Siman, Robert; Iqbal, Mohamed A.; Potter, Huntington
CS Dep. Neurobiol., Harvard Med. Sch., Boston, MA, 02115, USA
SO Journal of Neurochemistry (1993), 61(2), 567-77
CODEN: JONRA9; ISSN: 0022-3042
DT Journal
LA English
AB Cleavage after Met596 of the .beta.-amyloid precursor protein to generate the N-terminus of the amyloid .beta.-protein indicates the activity of a proteinase having chymotrypsin-like specificity. A chymotrypsin-like proteinase is further implicated in Alzheimer's disease by the increased synthesis of the proteinase inhibitor .alpha.1-antichymotrypsin in pathol. affected brain regions and by the presence in the amyloid deposits of inactivated forms of .alpha.1-antichymotrypsin (indicating irreversible binding to a target chymotrypsin-like proteinase). In the present report, the authors purified from rat brain a chymotrypsin-like proteinase that (a) binds with high affinity to human .alpha.1-antichymotrypsin, (b) proteolytically generates a .beta.-protein-contg. C-terminal fragment from full-length recombinant human .beta.-amyloid precursor protein, and (c) selectively cleaves methoxysuccinyl-Glu-Val-Lys-Met-p-nitroanilide (a substrate modeling the proteinase recognition domain for the .beta.-protein N-terminal cleavage site). Amino acid sequences of tryptic fragments of the purified rat brain chymotrypsin-like proteinase indicate an identity with rat mast cell proteinase I. Moreover, the ontogeny and compartmentalization of rat brain chymotrypsin-like proteinase are consistent with those of connective tissue-type mast cells in the meningeal and intracortical perivascular. Because these areas in human brain form extensive .beta.-amyloid deposits in Alzheimer's disease, Down's syndrome, and hereditary cerebral hemorrhage with amyloidosis of Dutch origin, the present findings suggest that a brain mast cell chymotrypsin-like proteinase may participate in generating perivascular .beta.-protein, which ultimately aggregates into .beta.-amyloid deposits.

L7 ANSWER 20 OF 48 CAPLUS COPYRIGHT 2003 ACS
AN 1994:479550 CAPLUS
DN 121:79550
TI Studies on brain proteases capable of degrading the .beta. amyloid precursor protein
AU Abraham, Carmela R.; Papastoitsis, Gregory; Razzaboni, Bronwyn L.; Kanemaru, Kazutomi; Pietropaolo, Michael; Conn, Kelly-Jo; Meckelein, Barbara
CS Sch. Med., Boston Univ., Boston, MA, 02118, USA
SO Portland Press Proceedings (1993), 6 (PROTEOLYSIS AND PROTEIN TURNOVER), 197-202
CODEN: POPPEF; ISSN: 0966-4068
DT Journal; General Review
LA English

AB A review and discussion with 35 refs. Several lines of evidence suggest that amyloid proteins may play a role in pathogenesis of Alzheimer's disease (AD). A no. of brain proteases have been isolated and characterized that have the potential to participate in the abnormal proteolytic processing of .beta. amyloid precursor protein seen in AD and, hence, form potentially important targets for therapeutic intervention.

L7 ANSWER 21 OF 48 CAPLUS COPYRIGHT 2003 ACS

AN 1992:509327 CAPLUS

DN 117:109327

TI .beta.-Amyloid precursor protein cleavage by a membrane-bound protease

AU Sisodia, Sangram S.

CS Sch. Med., Johns Hopkins Univ., Baltimore, MD, 21205, USA

SO Proceedings of the National Academy of Sciences of the United States of America (1992), 89(13), 6075-9

CODEN: PNASA6; ISSN: 0027-8424

DT Journal

LA English

AB The principal component of brain amyloid plaques in Alzheimer disease is .beta.-amyloid protein, a .apprxeq.4-kDa peptide derived from amyloid precursor proteins. Amyloid precursor proteins are secreted after proteolytic cleavage of the .beta.-amyloid peptide. In cultured cells, amyloid precursor protein is cleaved on the plasma membrane by a membrane-bound endoprotease and the specificity of peptide bond hydrolysis is largely independent of the primary sequence of the precursor. The principal determinants of the cleavage appear to be an .alpha.-helical conformation and the distance (12-13 residues) of the hydrolyzed bond from the plasma membrane.

L7 ANSWER 25 OF 48 CAPLUS COPYRIGHT 2003 ACS

AN 1992:548472 CAPLUS

DN 117:148472

TI Two-way cleavage of .beta.-amyloid protein precursor by multicatalytic proteinase

AU Kojima, Shinichi; Omori, Motoko

CS Res. Inst., Sumitomo Pharm. Co., Osaka, 554, Japan

SO FEBS Letters (1992), 304(1), 57-60

CODEN: FEBLAL; ISSN: 0014-5793

DT Journal

LA English

AB The .beta.-amyloid protein (.beta.-AP) derived from a .beta.-amyloid protein precursor (APP) is a hallmark of Alzheimer disease. The abundant generation of .beta.-AP suggests an abnormal processing of APP. The main APP-processing enzyme was purified from the rat brain and identified as a macroprotein-like multicatalytic proteinase. The purified enzyme cleaved the Gln15-Lys16 bond of .beta.-AP, but in the presence of Ca²⁺ the enzyme altered to cleave at the N-terminus of .beta.-AP to release the extracellular domain of .beta.-AP. Functional change in this multicatalytic proteinase may result in abnormal processing of APP in Alzheimer disease.

L7 ANSWER 27 OF 48 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 1992:245767 BIOSIS

DN BR42:116067

TI A SERINE PROTEASE FROM MONKEY AND ALZHEIMER'S BRAIN AND A CYSTEINE **PROTEASE FROM ALZHEIMER'S BRAIN DEGRADE THE AMYLOID PRECURSOR PROTEIN.**

AU ABRAHAM C R; RAZZABONI B; PAPASTOITSIS G

CS ARTHRITIS CENT., BOSTON UNIV. SCH. MED., BOSTON, MASS. 02118.

SO 21ST ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, NEW ORLEANS, LOUISIANA, USA, NOVEMBER 10-15, 1991. SOC NEUROSCI ABSTR. (1991) 17 (1-2), 1105.

CODEN: ASNEE5.

DT Conference

FS BR; OLD
LA English

L7 ANSWER 28 OF 48 CAPLUS COPYRIGHT 2003 ACS
AN 1991:119669 CAPLUS
DN 114:119669
TI A calcium-activated protease from Alzheimer's disease brain cleaves at the N-terminus of the amyloid .beta.-protein
AU Abraham, Carmela R.; Driscoll, James; Potter, Huntington; Van Nostrand, William E.; Tempst, Paul
CS Sch. Med., Boston Univ., Boston, MA, 02118, USA
SO Biochemical and Biophysical Research Communications (1991), 174(2), 790-6
CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English
AB Alzheimer's disease, Down's syndrome and to a lesser extent, normal aged brains exhibit abnormal extracellular deposits of amyloid. The major component of brain amyloid is the .beta.-protein, a 4Kd fragment of the larger B-protein precursor. The finding of the abnormally processed .beta.-protein and a protease inhibitor (.alpha.1-antichymotrypsin) in the amyloid deposits prompted the authors to search for proteases which may generate the .beta.-protein from its precursor. The presence and partial purifn. is reported of one such proteolytic activity from Alzheimer's brain. Normal physiol. C-terminal cleavage of the secreted form of the .beta.-protein precursor occurs in the middle of the .beta.-protein suggesting that the .beta.-protein accumulates due to an alternative degrdn. pathway. Apparently, the protease activity participates in this abnormal pathway.

L7 ANSWER 29 OF 48 CAPLUS COPYRIGHT 2003 ACS
AN 1991:79412 CAPLUS
DN 114:79412
TI Proteolytic cleavage of the Alzheimer's disease amyloid A4 precursor protein
AU Ishiura, Shoichi
CS Natl. Inst. Neurosci., NCNP, Tokyo, 187, Japan
SO Journal of Neurochemistry (1991), 56(2), 363-9
CODEN: JONRA9; ISSN: 0022-3042
DT Journal; General Review
LA English
AB A review with 60 refs. Amyloid A4 protein (.beta.-protein) is deposited in the brain of patients with Alzheimer disease (AD) as one of the main components of the extracellular cerebrovascular amyloid and neurofibrillary tangles. It is derived from a precursor protein and its formation is a rate-limiting step for brain degeneration in AD together with proteolytic cleavage. The topog. distribution of the proteinase and its substrates in the AD brain is discussed.

L7 ANSWER 33 OF 48 CAPLUS COPYRIGHT 2003 ACS
AN 1990:609064 CAPLUS
DN 113:209064
TI Activity and expression of amyloid precursor proteins possessing proteinase inhibitor regions
AU Kitaguchi, Nobuya; Shiojiri, Satoshi; Takahashi, Yasuyuki; Tokushima, Yasuo
CS Bio-Sci. Lab., Asahi Chem. Ind. Co. Ltd., Fuji, 416, Japan
SO Shinkei Kenkyu no Shinpo (1990), 34(3), 409-21
CODEN: SKNSAF; ISSN: 0001-8724
DT Journal; General Review
LA Japanese
AB A review with 5 refs. Cerebral deposits of amyloid .beta. protein (.beta.-AP) comprising about 40 amino acids, as senile plaque core and vascular amyloid, are characteristic of Alzheimer's disease (AD). Sensitive assays by the polymerase chain reaction method have revealed

that small amts. of mRNA species coding for novel .beta.-AP precursor proteins (APP), APP714 and APP563 (secreted type of APP751), exist in human brain, as well as larger amts. of mRNAs for APP695, APP751 and APP770. APP751 and APP770 comprise Kunitz type trypsin inhibitor regions (APPI). Several reports have opened discussions on the physiol. role of APPs: their C-terminal fragments show neurotoxic activity, secreted forms of APP are trophic for proliferation of fibroblasts, and APPI comprised by APP751 stimulates cell division. APPI was found to inhibit trypsin and chymotrypsin most strongly and also to inhibit leukocyte elastase and several blood-coagulation proteinases, but not to inhibit urokinase or thrombin. Utilizing specific probes for each type of APP mRNAs in RNA blot anal., the authors have found an increase of APP751 (1.1.apprx.1.3 fold) and APP770 (about 2 fold) mRNA levels in several regions of AD brain compared with age-matched controls. A similar increase of the ratio of APP751 plus APP770 mRNA in AD brain is also reported and an increase of APP695 mRNA has been found in specific brain regions. There have been several reports on detection of APPI in cerebrospinal fluid (CSF) by immunoblot anal. Both sol. forms of APPs, with APPI (112 kDa) and without APPI (91 kDa), have been found to be more abundant in CSF of AD than in controls by using a monoclonal antibody against APP695. By using an antiserum against synthetic APPI peptide, 125 kDa and 58 kDa APP have been found in CSF. The proteinases and their inhibitors are important for the formation of .beta.-AP fragment from APP.

=>

<-----User Break----->

=>